Gemelli Biotech develops non-invasive precision diagnostics leveraging microbiome discoveries for gastrointestinal diseases. The company provides clinicians with tools to definitively detect scientifically validated biomarkers for conditions like SIBO and IMO. This enables more optimal treatment strategies for patients suffering from various GI disorders.
Funding
$57.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BOFounders
Product
Problem
Diagnosing gastrointestinal diseases like SIBO, IMO, and IBS traditionally requires invasive procedures or tests that lack specificity, leading to delayed diagnoses and ineffective treatment plans. Patients often endure prolonged periods of discomfort and uncertainty while navigating complex diagnostic pathways.
Solution
Gemelli Biotech offers non-invasive, at-home diagnostic tests that utilize microbiome analysis and serology to identify biomarkers associated with specific gastrointestinal conditions. The Trio-Smart breath test measures hydrogen, methane, and hydrogen sulfide levels to detect SIBO, IMO, and intestinal sulfide overproduction (ISO). The IBS-Smart blood test measures anti-CdtB and anti-vinculin antibodies to diagnose post-infectious IBS. These tests provide clinicians with objective data to differentiate between various GI disorders, enabling targeted treatment strategies and improved patient outcomes. Patients can order the tests online or through their healthcare provider and receive results within days.
Target Audience
The primary target audience includes gastroenterologists, primary care physicians, and other healthcare providers who diagnose and treat gastrointestinal disorders, as well as individuals experiencing chronic GI symptoms such as bloating, abdominal pain, diarrhea, and constipation.
Features
- Trio-Smart: At-home breath test measuring hydrogen, methane, and hydrogen sulfide for comprehensive SIBO/IMO/ISO detection
- IBS-Smart: Antibody blood test for diagnosing post-infectious IBS by measuring anti-CdtB and anti-vinculin
- CLIA-certified lab processing ensures accuracy and reliability of test results
- Online ordering platform for convenient at-home sample collection and submission
- Results available within 7 days of lab receipt, delivered directly to patients or healthcare providers
- Doctor Discussion Guides and educational resources to facilitate informed conversations about test results and treatment options